Business
ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP™ in Immune Cell Cryopreservation Testing
ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP™ in Immune Cell Cryopreservation Testing.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\n \n ProtoKinetix, \n Incorporated (OTC: PKTX) (the \"Company\" or \"ProtoKinetix\") (www.protokinetix.com) \n and Proactive Immune Sciences (www.proactiveimmunesciences.com) \n today announce that they have entered into a joint research \n collaboration. The goal of the research will be to test the effect of \n the patented anti-aging glycopeptide AAGP™ on the immune cell \n cryopreservation protocols used by Proactive Immune Sciences.\n \n \n “We are excited about this new joint research collaboration and \n hope AAGP™ has some of the same positive effects, with respect to \n cryopreserving immune cells, that it is having on other cell lines,” \n says Jeff Schulz, CEO, Proactive Immune Sciences. “We are hoping \n to prove through our research that AAGP will have a positive affect on \n helping immune cells recover from the cryopreservation process. Any \n improvement in cell survival rate, or cell function could have \n significant, positive benefits for future treatments using cryopreserved \n immune cells.\n \n \n Pending a successful outcome of our research, the intent is for \n Proactive to enter into a licensing agreement with ProtoKinetix for the \n cryopreservation of immune cells. This will give Proactive customers the \n benefit of knowing their stored immune cells will perform at the highest \n levels possible should they require them for any immune cell based \n cancer or immune system reconstitution later in their life.”\n \n \n About \n Immune Cell Banking\n \n \n The initial phase of the research is expected to conclude later in 2017. \n Partial funding for the project has been provided by The National \n Research Council’s Industrial Research Assistance Program.\n \n \n About \n the National Research Council's Industrial Research Assistance Program\n \n \n Immune based interventions represent one of the fastest growing, most \n promising areas of personalized medicine. This is particularly true for \n cancer, which is largely a disease of immune failure. Therefore, there \n is a strong impetus for individuals to bank healthy immune cells at as \n early an age as possible, before these cells are compromised by \n infection, malignancy, or simply advanced immunological age. These cells \n can be used later on for any form of immunotherapy the client might \n require.\n \n...